- 1 Systematic Review
- 2 Review and methodological analysis of trials currently testing treatment and prevention
- 3 options for COVID-19 globally.
- 4 Paraskevi C. Fragkou^{1,2,§,*}, Drifa Belhadi^{3,4,§}, Charalampos D. Moschopoulos^{1,¥}, Nathan
- 5 Peiffer-Smadja^{3,5,¥}, François-Xavier Lescure^{3,5}, Hannah Janocha⁶, Emmanouil Karofylakis¹,
- 6 Yazdan Yazdanpanah^{3,5}, France Mentré^{3,4}, Chrysanthi Skevaki^{2,6}, Cédric Laouénan^{3,4,#},
- 7 Sotirios Tsiodras^{1,2,#} on behalf of the ESCMID Study Group for Respiratory Viruses.
- 8 ¹ 4th Department of Internal Medicine, Medical School, National and Kapodistrian University
- 9 of Athens, Attikon University Hospital, Athens, Greece
- ² European Society of Clinical Microbiology and Infectious Diseases (ESCMID) Study Group
- 11 for Respiratory Viruses (ESGREV)
- ³ Université de Paris, IAME, INSERM, F-75018 Paris, France
- 13 ⁴ Département d'Epidémiologie Biostatistiques et Recherche Clinique, Hôpital Bichat –
- 14 Claude-Bernard, AP-HP, 75018 Paris, France
- ⁵ Infectious Diseases Department, Bichat-Claude Bernard Hospital, Assistance-Publique
- 16 Hôpitaux de Paris, Paris, France
- 17 ⁶ Institute of Laboratory Medicine, Universities of Giessen and Marburg Lung Centre
- 18 (UGMLC), Philipps University Marburg, German Centre for Lung Research (DZL) Marburg,
- 19 Germany
- ^{*}Corresponding author: Paraskevi C. Fragkou, 4th Department of Internal Medicine,
- 21 Medical School, National and Kapodistrian University of Athens, Attikon University
- 22 Hospital, Chaidari, Athens, 12462, Greece. Tel: +306973388299, Fax: +30 2105326446,
- 23 Email: evita.fragou@gmail.com.

- 24 § Equal contribution as first authors
- 25 ¥ Equal contribution as second authors
- [#]Equal contribution as senior authors
- 27 **Abstract word count**: 294 words

28 **Main manuscript word count**: 3873 words

31

32

33

34

35

36

37

38

39

40

41

42

43

44

45

46

47

48

49

50

51

52

53

ABSTRACT Background: As COVID-19 cases continue to rise globally within an unprecedented short period of time, solid evidence from large randomised controlled trials is still lacking. Currently, numerous trials testing potential treatment and preventative options are undertaken globally. **Objectives:** We summarised all currently registered clinical trials examining treatment and prevention options for COVID-19. Additionally, we evaluated the quality of the retrieved interventional studies. **Data sources**: Clinicaltrials.gov, the Chinese Clinical Trial Registry and the European Union Clinical Trials Register were systematically searched. Study eligibility criteria: Registered clinical trials examining treatment and/or prevention options for COVID-19 were included. No language, country or study design restrictions were applied. We excluded withdrawn or cancelled studies and trials not reporting therapeutic or preventative strategies for COVID-19. Participants and interventions: No restrictions in terms of participants' age and medical background or type of intervention were enforced. Methods: The registries were searched using the term "coronavirus" or "COVID-19" from their inception until 26th March 2020. Additional manual search of the registries was also performed. Eligible studies were summarised and tabulated. Interventional trials were methodologically analysed, excluding expanded access studies and trials testing Traditional Chinese Medicine. **Results:** In total, 309 trials evaluating therapeutic management options, 23 studies assessing preventive strategies and 3 studies examining both were retrieved. Interventional treatment studies were mostly randomised (n=150, 76%) and open-label (n=73, 37%) with a median

54 number of planned inclusions of 90 (IQR 40-200). Major categories of interventions that are 55 currently being investigated are discussed. 56 Conclusion: Numerous clinical trials have been registered since the onset of the COVID-19 57 pandemic. Summarised data on these trials will assist physicians and researchers to promote 58 patient care and guide future research efforts for COVID-19 pandemic containment. 59 However, up to the end of March, 2020, significant information on reported trials was often 60 lacking. 61 62 **Keywords**: SARS-CoV-2; COVID-19; novel coronavirus; pneumonia; treatment; prevention; 63 antivirals; immunomodulators; anti-inflammatory; clinical trials. 64

INTRODUCTION

65

66

67

68

69

70

71

72

73

74

75

76

77

78

79

80

81

82

83

84

85

86

87

88

89

COVID-19 pandemic induced by the Severe Acute Respiratory Syndrome coronavirus 2 (SARS-CoV-2) has already affected most countries globally [1]. As of April 12, 2020, more than 1,690,000 COVID-19 cases have been officially reported leading to more than 150,900 deaths worldwide, with numbers constantly rising on a daily basis as the virus continues to spread exponentially [2,3]. The original source of SARS-CoV-2 is still debatable, though phylogenetic data analysis converge into the hypothesis that SARS-CoV-2 has possibly originated from bat SARS-like coronaviruses (CoVs) [4–6]. Human CoVs are positive-sense single-stranded RNA (+ssRNA) viruses belonging to the *Orthocoronavirinae* subfamily [7]. The analysis of viral genome as well as structural and non-structural proteins plays central role in identifying candidate treatment targets [7]. Notably, the SARS-CoV-2 surface spike glycoprotein (S-protein) is a key structural component that controls the viral interaction with hosts' angiotensin I converting enzyme 2 (ACE2) receptor in order to invade human epithelial cells [8]. Moreover, molecules directed against non-structural proteins such as the viral protease or pathways imperative for viral genome replication, alone or along with boosters or regulators of the host's immune system, constitute promising therapeutic strategies[8,9]. Given the steep upsurge of COVID-19 cases worldwide within an unprecedented short period of time, we are still waiting for solid evidence from large randomised controlled trials regarding targeted antiviral treatments. In this systematic review, we aim firstly to summarise the data on all currently tested treatment and prevention options for the COVID-19 disease, and secondly to methodologically analyse and evaluate the quality of the registered interventional studies.

METHODS

91

92

93

94

95

96

97

98

99

100

101

102

103

104

105

106

107

108

109

110

111

112

113

Registered clinical trials were systematically searched at the ClinicalTrials.gov database[10], the Chinese Clinical Trial Registry[11] and the European Union Clinical Trials Register [12] from their inception up to 26th March 2020 using the search terms "coronavirus" or "COVID-19". Additional manual search of the registries was performed for possibly unidentified studies. No language, country or study design restrictions were applied. Participants of any age and medical background with or at risk for COVID-19 were included, as were any currently tested intervention related to the treatment or prevention of COVID-19. We excluded withdrawn or cancelled studies and trials not reporting therapeutic or preventative measures for COVID-19. Eligible studies were summarised and tabulated. Methodological analysis of the interventional studies was performed. Traditional Chinese Medicine (TCM) and homeopathy were excluded from the in-depth qualitative assessment, as we have no expertise to analyse clinical trials testing these agents that rely on controversial scientific rationale [13,14]. We evaluated the study design, number of planned inclusions and primary outcomes of interventional studies, excluding retrospective and "expanded access" studies. Studies were also analysed according to their primary endpoint, i.e. clinical, virological (viral excretion in clinical samples), radiological (imaging results such as CT-scan or X-rays), or biological / immunological (complete blood count, CR, CD8+/CD4+ T cells count, etc.). This review was conducted according to the PRISMA guidelines [15]. **RESULTS** 1. General data retrieved In total, 335 studies were retrieved, including 309 trials evaluating therapeutic molecules, devices and other management options, 23 studies assessing medications, vaccines under development and other preventive strategies, and 3 studies examining both (Figure 1, Table S1, Table S2). An overview of currently tested therapeutic interventions is presented in Figure 2 and Figure 3. 2. **Main treatment interventions Protease Inhibitors** Lopinavir is a protease inhibitor (PI) active against human immunodeficiency virus 1 (HIV-1) infection. The main coronavirus proteinase (3C-like proteinase or 3CL^{pro}) plays a key role in processing viral polyproteins [16,17]. PIs effectively inhibit the 3CL^{pro} enzyme, thus posing a possibly potent therapeutic agent against SARS-CoV-2 infection. PIs have shown effectiveness against SARS-CoV, MERS-CoV and SARS-CoV-2 viruses in in vitro susceptibility models [18–21]. During SARS-CoV epidemic, lopinavir boosted by ritonavir (a cytochrome P450-3A4 inhibitor) with or without ribavirin, significantly reduced adverse outcomes including mortality[22]. The MIRACLE trial that examines the efficacy of ritonavir boosted lopinavir combined with recombinant interferon-beta 1b (IFN-β1b) in the treatment of MERS, is currently undertaken in Saudi Arabia and results are pending [23]. For COVID-19, lopinavir/ritonavir combined with or without other agents has been reported to successfully reduce adverse outcomes in sporadic cases from China [24-27]. These promising reports have set the ground for numerous trials addressing the safety and efficacy of PIs in SARS-CoV-2 infection (Table 1). Other PIs that are currently being assessed are ritonavir boosted ASC09 (a novel PI), cobicistat boosted darunavir as well as the NS3/4A protease inhibitor danoprevir combined with ritonavir (Table 1, Table S1).

RNA polymerase inhibitors

114

115

116

117

118

119

120

121

122

123

124

125

126

127

128

129

130

131

132

133

134

135

136

139

140

141

142

143

144

145

146

147

148

149

150

151

152

153

154

155

156

157

158

159

160

161

162

SARS-CoV-2 and SARS-CoV RNA-dependent RNA polymerase (RdRp) share 96% sequence identity; this has justified the assumption that inhibitors effective against SARS-CoV could have similar inhibitory effects against SARS-CoV-2[28]. Nucleoside analogues compete with natural nucleosides for the RdRp active site, thus inhibiting the viral genome replication [29]. Current research efforts focus on repurposing older molecules in COVID-19 treatment, as their safety profile has already been documented [30]. Remdesivir (GS-5734TM) is an adenosine analogue with broad-spectrum antiviral properties [31]. Preclinical data demonstrated the efficacy of remdesivir against SARS-CoV and MERS-CoV, as it has the potential to outcompete the proofreading ability of coronavirus exonuclease, and carries a high genetic resistance barrier [21,28,30,32]. Wang et al. confirmed its in vitro efficacy against SARS-CoV-2 [33]. Currently, it is investigated in 7 randomised, controlled trials (Table 1, Table S1). Favipiravir is a nucleoside analogue inhibiting the RNA polymerase, initially approved for the treatment of novel influenza viruses [34]. It is also effective against a broad range of viruses, including positive-sense single-stranded RNA viruses [34]. Since there have been some promising in vitro results for its efficacy against SARS-CoV-2, favipiravir is now being investigated in 8 clinical trials. Ribavirin is a guanosine analogue that inhibits inosine monophosphate dehydrogenase required for the synthesis of guanosine triphosphate, leading to lethal mutagenesis of RNA genome [35]. Ribavirin was used in SARS epidemic in combination with either lopinavir/ritonavir or interferon alpha (IFN-α), and these combinations are currently recommended by the China National Practice Guidelines for the treatment of severe COVID-19 [22,36]. Azvudine, an azidocytidine analogue that inhibits viral reverse transcriptase, has been effective against HIV, hepatitis B and C viruses [37]. Its efficacy against SARS-CoV-2 is

164

165

166

167

168

169

170

171

172

173

174

175

176

177

178

179

180

181

182

183

184

185

186

being tested in 3 ongoing clinical trials (Table 1, Table S1). Another nucleoside analogue undergoing investigation for COVID-19 pneumonia is emtricitabine/tenofovir alafenamide. Anti-malaria drugs Chloroquine and hydroxychloroquine are currently licensed for the treatment of malaria and autoimmune diseases [38]. However, they have also been studied against several viruses with promising in vitro results, never confirmed in humans [39–41]. As weak bases, they are concentrated in acidic intra-cellular organelles, leading to alkalization and distraction of the low pH-dependent steps of viral replication, including viral-cell fusion and uncoating [38,40]. Moreover, they impair the terminal glycosylation of ACE2 receptor in Golgi apparatus, thus inhibiting the viral penetration into the host cells [42]. As they are accumulated in lymphocytes and macrophages, these drugs reduce secretion of proinflammatory cytokines, and particularly of tumour necrosis factor alpha (TNF- α) [41]. Experimental data demonstrated that chloroquine is highly effective in vitro against SARS-CoV-2 in an estimated effective concentration that is easily achievable with standard dosing regimens [33]. Preliminary results from small studies suggested the effectiveness of chloroquine, alone or combined with azithromycin, in viral clearance, inhibition of pneumonia exacerbation, improvement of lung imaging and shortening of the disease course [43,44]. However, clinical trials with a control group are needed to provide reliable answers for clinicians. Immunomodulators and anti-inflammatory drugs Virus-induced exuberant immune response leading to cytokine storm syndrome (CSS) and secondary haemophagocytic lymphohistiocytosis (HLH) is probably the underlying

188

189

190

191

192

193

194

195

196

197

198

199

200

201

202

203

204

205

206

207

208

209

210

211

pathogenetic mechanism that leads to critical and often fatal COVID-19 infection [45,46]. Hyperinflammation is associated with acute respiratory distress syndrome (ARDS) and fulminant multi-organ failure thatarefatal if left untreated. In this context, immunosuppressors (along with antivirals) may play a key role in counteracting severe SARS-CoV-2 infection [45]. Preliminary data from COVID-19 patients in China reported significantly higher interleukin (IL)-6 levels in patients with critical COVID-19 disease than those with severe or mild disease [47]. Tocilizumab and sarilumab, both humanised monoclonal antibodies (mAbs) against the IL-6 receptor, are currently evaluated in 14 clinical trials (Table 1, Table S1); tocilizumab, in particular, improved symptoms and laboratory parameters in a small retrospective study in China [48]. Various other molecules oriented against different cytokines, as well as intra- and extra-cellular inflammatory pathways, are currently being tested in COVID-19 including: adalimumab, anti-programmed cell death protein 1 mAbs, bevacizumab, ixekizumab, eculizumab, human recombinant IL-2, inhibitors of NLRP3 inflammasome activation (tranilast), Janus Kinase inhibitors, fingolimod and a recombinant fusion protein targeting an immune pathway checkpoint (CD24Fc). Clinical trials on other immunotherapies (i.e.gimsilumab, siltuximab, lenzilumab and leronlimab) have been proposed, but havenot been registered yet. Immunomodulators licensed for haematological and rheumatological conditions (such as leflunomide and thalidomide), as well as colchicine that counteracts the assembly of the NLRP3 inflammasome, are also being studied for their therapeutic use against SARS-CoV-2 (Table 1, Table S1) [49]. The immunomodulatory effects of macrolide antibiotics, as well as their pharmacodynamic property to achieve at least 10-fold higher concentrations in epithelial lung fluid than in serum, have led researchers to repurpose them against SARS-CoV-2 (Table 1, Table S1)

213

214

215

216

217

218

219

220

221

222

223

224

225

226

227

228

229

230

231

232

233

234

235

[50,51]. Preliminary results of a study have shownsignificant viral load reduction in patients treated withhydroxychloroquine plus azithromycin [43]. Corticosteroids are major anti-inflammatory drugs, with a conflicting safety profile in severe viral infections [52]. However, their use is currently recommended by the European Society of Intensive Care Medicine in COVID-19 cases with shock and/or evidence of CSS/HLH and/or mechanically ventilated patients with ARDS [53]. Corticosteroids are being tested in 11 clinical trials (Table 1, Table S1). Finally, immunostimulatory molecules that enhance the hosts' immune response against the invading pathogen, like IFN- α , interferon beta (IFN- β), the recombinant protein produced by DNA-shuffling of IFN-α (novaferon), the inactivated Mycobacterium vaccine and thymosin a1, are evaluated as viable therapeutic options in various combinations against SARS-CoV-2 [54]. Membrane fusion inhibitors and inhibitors of ACE2 receptor connection SARS-CoV-2S-protein bindsACE2 receptor on the epithelial cells' membrane [55]. The host's type II transmembrane serine protease (TMPRSS2) facilitates membrane fusion and augments viral internalization by cleaving and activating the S-protein [56,57]. These proteins, being an integral part of the viral life cycle, can be used as possible therapeutic targets. ACE inhibitors (ACEi) selectively inhibit ACE1 but not ACE2, as they are structurally different enzymes [58]. Experimental animal models show that angiotensin II type 1 receptor blockers (ARBs) and ACEi may up-regulate ACE2 expression; although this raised concerns that ACEi and ARBs may be associated with a more severe form of COVID-19, there is no evidence supporting that ACE2 up-regulation augments the virulence or the penetration of the

virus into the hosts' cells as of yet [58,59]. Contrarily, renin-angiotensin system (RAS) inhibition may ameliorate the over-accumulation of angiotensin II induced by the downregulation of ACE2 noted in other CoVs infection, thus possibly protecting against the development of fulminant myocarditis and ARDS [58]. In spite of controversial data, 2 randomised controlled trialstesting losartan are currently undertaken in the USA. Camostat mesilate is a potent serine protease inhibitor, inhibiting the TMPRSS2 and is approved for chronic pancreatitis [60]. In vitro experiments have shown that camostat is effective against SARS-CoV-2[61]. Nafamostat, another inhibitor of TMPRSS2 has been suggested in COVID-19 therapy, but no registered trials are available yet. Umifenovir is a small indole derivative with a broad-spectrum antiviral activity developed about 30 years ago [62,63]. Although it is currently used in Russia and China to combat influenza, it has shown in vitro activity against numerous DNA and RNA viruses including SARS-CoV [62,64,65]. It primarily targets the interaction between viral capsid and the membrane of the host cell by inhibiting the attachment, the fusion and the internalization of the virus [62]. Moreover, umifenovir has direct virucidal effects against enveloped viruses through interaction with the viral lipid envelope or with key residues within structural proteins of virions [62,65,66]. Limited data support that umifenovir may exhibit immunomodulatory effects by stimulating hosts' humoral immune response, interferon production, and phagocytes' activation [67]. A small retrospective study in China demonstrated some promising results regarding its effectiveness against SARS-CoV-2 when used in combination with lopinavir/ritonavir [68]. Currently 11 relevant clinical trials are in progress globally (Table 1, Table S1).

Passive immunization

236

237

238

239

240

241

242

243

244

245

246

247

248

249

250

251

252

253

254

255

256

257

258

261

262

263

264

265

266

267

268

269

270

271

272

273

274

275

276

277

278

279

280

281

282

283

284

The use of convalescent plasma (CP) to passively immunise patients against viral pathogens has been previously reported, especially when no other treatment options were available [69]. CP obtained from recovering patients was usedduringthe SARS epidemic; two retrospective studies demonstrated that CP administration in SARS patients reduced duration of hospitalisation and mortality rates, when treatment with ribavirin and corticosteroids failed [70-72].A meta-analysis of patients with severe respiratory infection induced by various viruses showed a statistically significant reduction of 75% in mortality odds in those who received CP across all viral aetiologies, including the influenza A 2009 pandemic strain (H1N1pdm09) and SARS-CoV[73]. Evidence of survival benefit was noted after early administration, while no serious adverse effects were reported. Although results are pending from 10 relevant clinical trials, the potential short-lasting immunity after CoV infection has raised uncertaintyregardingthe clinical efficacy of CP antibodies in clinical practice[74,75]. Cell therapies Mesenchymal stromal cells (MSCs) exhibit immunomodulating qualities, may skew immune cell differentiation and have shown promise in H5N1-associated acute lung injury in preclinical models[76]. A pilot study involving MSC transplantation in 7 patients with COVID-19 resulted in cure or significant improvement of pulmonary function and symptoms without adverse effects [77]. MSCs may partially accumulate in lungs and improve the pulmonary microenvironment. A significant induction of regulatory dendritic cells(DCs), along with a shift from Th1 towards Th2 immune responses, was also observed [77]. Other clinical trials utilizing MSCs for curing COVID-19 are ongoing (Table 1, Table S1). MSC-derived exosomes are extracellular bodies mediating intercellular communication, containing mRNAs, miRNAs, lipids, growth factors and cytokines, that possibly exert the

286

287

288

289

290

291

292

293

294

295

296

297

298

299

300

301

302

303

304

305

306

307

308

paracrine immunoregulatory effects of MSC [78]. Furthermore, MSC-exosomes' administration is associated with lower risks (e.g.tumour formation, immunogenicity) compared to the intravenous injection of MSCs [79]. Natural killer cells have shown promising results as adoptive immunotherapy in various cancers, and may also be potent effector cells in the SARS-CoV-2 infection. A phase 1 clinical trial has been launched to determine their efficacy (Table S1). Lastly, ozone therapy may inactivate viruses, among other pathogens, and activate the immune system via upregulation of Th1 cytokines including IFN and TNF; as such,3 trials have been launched to evaluate ozone autohaemotherapy efficacy in COVID-19 [80]. 3. Main preventative measures The World Health Organization (WHO) and the European Centre for Disease Prevention and Control (ECDC) emphasise the role of screening, precaution measures, exposure prevention and environmental disinfection as the mainstay of COVID-19 prevention[81,82]. As no effective preventative options are available yet, several clinical trials are under way to explore the efficacy of various prevention strategies (Table 2, Table S2). Many studies are currently evaluating the efficacy of TCM in COVID-19 prevention in China. Importantly, at least 4 vaccines are under development. Among them, an mRNA-based vaccine encoding the S-protein is being assessed for its safety, reactogenicity and efficacy against SARS-CoV-2 (Table 2, Table S2). Besides the registered trials, other large companies have also announced the initiation of vaccine development [83,84]. Other preventative molecules include hydroxychloroquine and the recombinant human interferon α1b spray. In the USA, exposed individuals are randomised to hydroxychloroquine or placebo, evaluating the agent'spotential as post-exposure prophylaxis (NCT04308668,

Table S2). Furthermore, another randomised clinical trial evaluates the efficacy of a 3-month course of chloroquine in at-risk healthcare personnel (NCT04303507, Table S2). Finally, the live attenuated strain of Mycobacterium bovis is expected to be tested as a preventative strategy against COVID-19 among healthcare professionals, in Australia and France. 4. Methodological analysis of interventional studies **Study Populations** In total, 198 interventional treatment and 16 prevention trials were included in the methodological analysis respectively (Table 3). Among the eligible treatment studies, children recruitment (i.e.< 14 years old) was reported in 7 clinical trials in total: 1 testing darunavir with cobicistat (NCT04252274); 2 on human stem cells transfusion (ChiCTR2000029606, ChiCTR2000030944); 1 testing hydroxycholoroquine (EudraCT Number: 2020-000890-25); 1 using tocilizumab (NCT04317092); and 1 assessing nutritional supplements (NCT04323345) (Table S1). With respect to relevant prevention studies, children were included in 2 vaccine trials(NCT04276896and NCT04299724) as shown in Table S2.

Study designs

309

310

311

312

313

314

315

316

317

318

319

320

321

322

323

324

325

326

327

328

329

330

Phase IV and phase III treatment trials were the most commonly reported interventional study types (n=40, 20% and n=35, 18% respectively) as demonstrated in Table 3. Nonetheless, the majority of registered trials do not disclose the study phase (n=83, 42%).

In terms of blinding, 73 open-label (37%), 31 double-blinded (16%), and 16 single-blinded (8%) studies were retrieved. Most trials were randomised (n=150, 76%) with a parallel

assignment between arms. The median (IQR) number of planned inclusions is 90 (40-200) with a range of 5 to 6000 participants. Phase III and phase I prevention studies were the most commonly reported ones (n=6, 38%) and n=3, 19% respectively, Table 3). As with treatment trials, many prevention trials do not report the study phase (n=4, 25%). Regarding prevention studies' blinding, 6double-blinded (38%), 5open-label (31%), and 2 single-blinded (13%) were found. Most studies were randomised (n=10, 63%) with a parallel assignment design. The median (IQR) number of planned inclusions is 513 (177-2958) ranging from 45 to 7576 participants. Treatments and interventions Various types of interventions are currently evaluated; however, their appraisal is limited by the lack of reported data concerning the treatment dose and duration. Figure 4 demonstrates the number of trials by the median of planned inclusions per trial for the ten most frequently encountered therapies. Although remdesivir is tested in only 7 trials, these studies have the highest median number of planned inclusions per trial (453, IQR 397-650). On the other hand, cell therapies are assessed by the highest number of trials (n=25), but with a disproportionately low median number of planned inclusions (30, IQR 20-60). Figure 5 shows the total number of planned inclusions and the number of clinical trials for the ten most frequently studied treatments, with hydroxychloroquine being the treatment associated with

Primary endpoints and outcomes

the highest total number (10,146 planned iclusions).

331

332

333

334

335

336

337

338

339

340

341

342

343

344

345

346

347

348

349

350

351

352

A clinical primary outcome was defined in 128 therapeutic trials (65%; Table 3); most of them focused on the symptoms' evolution such as time to clinical recovery, the proportion of patients with clinical improvement or deterioration, length of hospitalisation or mortality. A number of scores are utilized as primary outcomes such as the ordinal 7-point scale adapted from the WHO master protocol, the lung injury score, the pneumonia severity index or the National Early Warning Score 2 score [85–87]. Most prevention studies disclose a clinical primary outcome (13 studies, 81%), while virological, radiological and biological/immunological primary endpoints were reported in 39 (20%), 19 (10%), and 12 (6%) studies respectively (Table 3).

DISCUSSION

354

355

356

357

358

359

360

361

362

363

364

365

366

367

368

369

370

371

372

373

374

375

376

377

378

The SARS-CoV-2 is the third emerging coronavirus of the last 20 years, but the one that has led to an evolving pandemic, a fact that urgently requires the implementation of novel therapeutics. However, repurposing of existing drugs is a viable and less time-consuming alternative; licensed broad-spectrum antiviral agents with a well-documented safety profile are currently tested against SARS-CoV-2. Alternatively, screening of chemical compounds' libraries may be useful in the discovery of an efficacious treatment against COVID-19 disease [8]. In this review, we have summarised and methodologically appraised the ongoing therapeutic and preventive trials for COVID-19.

Therapeutic strategies should follow the two-phased immune response to COVID-19. Initially, treatment should aim at strengthening the host's immune response against the virus, and inhibiting the viral replication [88]. Early initiation of antiviral therapy has been proved beneficial for the prognosis of patients[89]. As advanced age correlates with higher viral loads, older patients could strongly benefit from the prompt initiation of antivirals[90]. Moreover, high inflammatory cytokine levels have been correlated with disease severity and

380

381

382

383

384

385

386

387

388

389

390

391

392

393

394

395

396

397

398

399

400

401

402

the extent of lung damage[91]. Thus, in the later phase of the infection, patients could be availed by anti-inflammatory therapeutic approaches such as the Janus kinase inhibitors, blood purification or tocilizumab [92,93]. The Chinese National Health Commission recommends antiviral therapy with the protease inhibitors lopinavir/ritonavir. Other recommended antiviral agents include interferon alpha and chloroquine phosphate [93]. Advantages of chloroquine include its long clinical history, known side effects and low cost, which render it a good candidate for global use[33]. The broad-spectrum antiviral agent remdesivir has successfully been used in individual COVID-19 cases by the Washington Department of Health[94]. Effectiveness of both chloroquine and remdesivir against COVID-19 remains to be seen in ongoing trials. Prevention is a key player in combating pandemics. The mRNA 1273 vaccine, is currently in phase I, but is not expected to be commercially available this year[95]. The prophylactic potential of hydroxychloroquine/chloroquine is also actively being examined among healthcare professionals[96]. Moreover, prompt testing and isolation are of utmost importance for disease prevention. At the moment, real-time quantitative polymerase chain reaction is the reference standard in diagnostics [97]. The FDA has recently announced the authorisation of rapid molecular tests that are capable of delivering results within minutes, thus facilitating early treatment initiation (when viral loads are highest) and timely isolation [90,98,99]. Based on the retrieved data, cell therapies and hydroxychloroquine were the most frequently evaluated candidate therapies (25 and 22 trials respectively), while remdesivir was associated with the highest median number of planned inclusions per trial (453, IQR 397-650). Although TCMs and homeopathy represent a large proportion of the identified interventional studies, we excluded them from our methodological analysis as we do not have the expertise to analyse clinical trials testing these agents.

404

405

406

407

408

409

410

411

412

413

414

415

416

417

418

419

420

421

422

423

424

425

426

427

428

This review shows the considerable amount of clinical trials that are currently registered. Although the number of identified trials was high, there were several methodological caveats. Firstly, study design data and details on the interventions being assessed were often lacking. This hampers the available information to researchers and relevant stakeholders, and potentially influences the discovery of successful treatments. Secondly, most trials, and especially those registered at the beginning of the pandemic, disclosed low participant numbers, which may impact the robustness of their future results. However, these numbers should be cautiously interpreted, as they represent the anticipated, and not the actual number of inclusions. Thirdly, reported primary endpoints were highly heterogeneous among studies. In our opinion, the application of clinical primary endpoints should be encouraged in an infection where the association between the clinical status and viral clearance, radiological or immunological evolution is obscure. The identification of the best therapeutic approach is challenging, especially in the context of a pandemic with thousands of casualties. Our study underlines the need to meticulously register as many study details as possible on international registries during outbreaks, in order to guide the development and enhance the consistency of future trials. The development of clinical trials during an outbreak is an adaptive process and new evidence emerges at an impressive rate. A review of the early registered clinical trials is an important asset for researchers and methodologists. These results might encourage transparency when developing and registering future clinical trials and help improve their methodology, hence the robustness of their results. In the absence of reliable vaccines and therapies, disease containment plays a pivotal role, as has been recently observed in China. Undertaking actions such as nationwide temperature measurements, health recommendations, detection and strict isolation proved to slow down the transmission rate [100]. The time thereby won is precious for the development of therapies and vaccines. This approach is especially useful for countries with weaker health

systems that lack sufficient medical supplies and infrastructure, and often depend on the support of the international community. Transparency declaration Conflict of interest: For YY: Chair of the Global Research Collaboration for Infectious Disease Preparedness (GloPID-R) and the coordinator of REsearch and ACTion targeting emerging infectious diseases (REACTing). For CS: Consultancy and research funding, Hycor Biomedical and Thermo Fisher Scientific; Consultancy, BencardAllergie; Research Funding, Mead Johnson Nutrition (MJN). Supported by Universities Giessen and Marburg Lung Centre (UGMLC), the German Centre for Lung Research (DZL), University Hospital Giessen and Marburg (UKGM) research funding according to article 2, section 3 cooperation agreement, and the Deutsche Forschungsgemeinschaft (DFG)-funded-SFB 1021 (C04), -KFO 309 (P10), and SK 317/1-1 (Project number 428518790). All grants are outside the submitted work. *Funding*: No external funding was received for this study. Author contributions: Conception and design: PCF, ST, DB, NPS, FM, CL. Acquisition of data: PCF, EK, CDM, HJ, CS, DB, NPS, YY. Interpretation of data: all authors. Drafting the article: PCF, EK, CDM, HJ, CS, DB, NPS, FM, CL, YY. Revising critically the manuscript for important intellectual content: PCF, CS, ST. PCF and DB contributed equally as first authors, CDM and NPS contributed equally as second authors, CL and ST contributed equally as senior authors. All authors approved the final version of the manuscript submitted.

REFERENCES

429

430

431

432

433

434

435

436

437

438

439

440

441

442

443

444

445

446

447

448

449

450

452	[1]	Interim Guidance: Healthcare Professionals 2019-nCoV CDC n.d.
453		https://www.cdc.gov/coronavirus/2019-nCoV/hcp/clinical-criteria.html (accessed
454		April 2, 2020).
455	[2]	Situation reports n.d. https://www.who.int/emergencies/diseases/novel-coronavirus-
456		2019/situation-reports/ (accessed April 2, 2020).
457	[3]	Coronavirus disease 2019 (COVID-19) pandemic: increased transmission in the
458		EU/EEA and the UK – seventh update. n.d.
459	[4]	Paraskevis D, Kostaki EG, Magiorkinis G, Panayiotakopoulos G, Sourvinos G,
460		Tsiodras S. Full-genome evolutionary analysis of the novel corona virus (2019-nCoV)
461		rejects the hypothesis of emergence as a result of a recent recombination event. Infect
462		Genet Evol 2020;79:104212. https://doi.org/10.1016/j.meegid.2020.104212.
463	[5]	Lu R, Zhao X, Li J, Niu P, Yang B, Wu H, et al. Genomic characterisation and
464		epidemiology of 2019 novel coronavirus: implications for virus origins and receptor
465		binding. Lancet 2020;395:565–74. https://doi.org/10.1016/S0140-6736(20)30251-8.
466	[6]	Benvenuto D, Giovanetti M, Ciccozzi A, Spoto S, Angeletti S, Ciccozzi M. The 2019-
467		new coronavirus epidemic: Evidence for virus evolution. J Med Virol 2020;92:455–9.
468		https://doi.org/10.1002/jmv.25688.
469	[7]	Harrison C. Coronavirus puts drug repurposing on the fast track. Nat Biotechnol 2020.
470		https://doi.org/10.1038/d41587-020-00003-1.
471	[8]	Lu H. Drug treatment options for the 2019-new coronavirus (2019-nCoV). Biosci
472		Trends 2020;14:69–71. https://doi.org/10.5582/bst.2020.01020.
473	[9]	Zhang L, Liu Y. Potential interventions for novel coronavirus in China: A systematic
474		review. J Med Virol 2020;92:479–90. https://doi.org/10.1002/jmv.25707.
475	[10]	Home - ClinicalTrials.gov n.d. https://clinicaltrials.gov/ (accessed April 2, 2020).

476	[11]	Chinese Clinical Trial Register (ChiCTR) - The world health organization
477		international clinical trials registered organization registered platform n.d.
478		http://www.chictr.org.cn/searchprojen.aspx (accessed April 2, 2020).
479	[12]	EU Clinical Trials Register - Update n.d. https://www.clinicaltrialsregister.eu/
480		(accessed April 2, 2020).
481	[13]	Hard to swallow. Nature 2007;448:105–6. https://doi.org/10.1038/448106a.
482	[14]	Ernst E. Homeopathy, a "helpful placebo" or an unethical intervention? Trends
483		Pharmacol Sci 2010;31:1. https://doi.org/10.1016/j.tips.2009.10.005.
484	[15]	Moher D, Liberati A, Tetzlaff J, Altman DG, Altman D, Antes G, et al. Preferred
485		reporting items for systematic reviews and meta-analyses: The PRISMA statement.
486		PLoS Med 2009;6. https://doi.org/10.1371/journal.pmed.1000097.
487	[16]	Zhang L, Lin D, Kusov Y, Nian Y, Ma Q, Wang J, et al. α-Ketoamides as Broad-
488		Spectrum Inhibitors of Coronavirus and Enterovirus Replication: Structure-Based
489		Design, Synthesis, and Activity Assessment. J Med Chem 2020.
490		https://doi.org/10.1021/acs.jmedchem.9b01828.
491	[17]	Fan K, Wei P, Feng Q, Chen S, Huang C, Ma L, et al. Biosynthesis, purification, and
492		substrate specificity of severe acute respiratory syndrome coronavirus 3C-like
493		proteinase. J Biol Chem 2004;279:1637–42. https://doi.org/10.1074/jbc.M310875200.
494	[18]	Nukoolkarn V, Lee VS, Malaisree M, Aruksakulwong O, Hannongbua S. Molecular
495		dynamic simulations analysis of ritonavir and lopinavir as SARS-CoV 3CL(pro)
496		$inhibitors.\ J\ Theor\ Biol\ 2008; 254: 861-7.\ https://doi.org/10.1016/j.jtbi.2008.07.030.$
497	[19]	Chen F, Chan KH, Jiang Y, Kao RYT, Lu HT, Fan KW, et al. In vitro susceptibility of
498		10 clinical isolates of SARS coronavirus to selected antiviral compounds. J Clin Virol
499		2004;31:69–75. https://doi.org/10.1016/j.jcv.2004.03.003.

500	[20]	de Wilde AH, Jochmans D, Posthuma CC, Zevenhoven-Dobbe JC, van Nieuwkoop S,
501		Bestebroer TM, et al. Screening of an FDA-approved compound library identifies four
502		small-molecule inhibitors of Middle East respiratory syndrome coronavirus replication
503		in cell culture. Antimicrob Agents Chemother 2014;58:4875–84.
504		https://doi.org/10.1128/AAC.03011-14.
505	[21]	Sheahan TP, Sims AC, Leist SR, Schäfer A, Won J, Brown AJ, et al. Comparative
506		therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon
507		beta against MERS-CoV. Nat Commun 2020;11:222. https://doi.org/10.1038/s41467-
508		019-13940-6.
509	[22]	Chu CM, Cheng VCC, Hung IFN, Wong MML, Chan KH, Chan KS, et al. Role of
510		lopinavir/ritonavir in the treatment of SARS: initial virological and clinical findings.
511		Thorax 2004;59:252–6. https://doi.org/10.1136/thorax.2003.012658.
512	[23]	Arabi YM, Alothman A, Balkhy HH, Al-Dawood A, AlJohani S, Al Harbi S, et al.
513		Treatment of Middle East Respiratory Syndrome with a combination of lopinavir-
514		ritonavir and interferon- $\beta1b$ (MIRACLE trial): study protocol for a randomized
515		controlled trial. Trials 2018;19:81. https://doi.org/10.1186/s13063-017-2427-0.
516	[24]	Xu K, Cai H, Shen Y, Ni Q, Chen Y, Hu S, et al. [Management of corona virus
517		disease-19 (COVID-19): the Zhejiang experience]. Zhejiang Da Xue Xue Bao Yi Xue
518		Ban 2020;49:0.
519	[25]	Han W, Quan B, Guo Y, Zhang J, Lu Y, Feng G, et al. The course of clinical diagnosis
520		and treatment of a case infected with coronavirus disease 2019. J Med Virol
521		2020;92:461–3. https://doi.org/10.1002/jmv.25711.
522	[26]	Lim J, Jeon S, Shin HY, Kim MJ, Seong YM, Lee WJ, et al. Case of the index patient
523		who caused tertiary transmission of coronavirus disease 2019 in Korea: The
524		application of lopinavir/ritonavir for the treatment of COVID-19 pneumonia

525		monitored by quantitative RT-PCR. J Korean Med Sci 2020;35.
526		https://doi.org/10.3346/jkms.2020.35.e79.
527	[27]	Wang Z, Chen X, Lu Y, Chen F, Zhang W. Clinical characteristics and therapeutic
528		procedure for four cases with 2019 novel coronavirus pneumonia receiving combined
529		Chinese and Western medicine treatment. Biosci Trends 2020;14:64–8.
530		https://doi.org/10.5582/bst.2020.01030.
531	[28]	Morse JS, Lalonde T, Xu S, Liu WR. Learning from the Past: Possible Urgent
532		Prevention and Treatment Options for Severe Acute Respiratory Infections Caused by
533		2019-nCoV. Chembiochem 2020;21:730–8. https://doi.org/10.1002/cbic.202000047.
534	[29]	Elfiky AA. Anti-HCV, nucleotide inhibitors, repurposing against COVID-19. Life Sci
535		2020;248:117477. https://doi.org/10.1016/j.lfs.2020.117477.
536	[30]	Martinez MA. Compounds with therapeutic potential against novel respiratory 2019
537		coronavirus. Antimicrob Agents Chemother 2020:1–18.
538		https://doi.org/10.1128/AAC.00399-20.
539	[31]	Warren TK, Jordan R, Lo MK, Ray AS, Mackman RL, Soloveva V, et al. Therapeutic
540		efficacy of the small molecule GS-5734 against Ebola virus in rhesus monkeys. Nature
541		2016;531:381–5. https://doi.org/10.1038/nature17180.
542	[32]	Agostini ML, Andres EL, Sims AC, Graham RL, Sheahan TP, Lu X, et al.
543		Coronavirus Susceptibility to the Antiviral Remdesivir (GS-5734) Is Mediated by the
544		Viral Polymerase and the Proofreading Exoribonuclease. MBio 2018;9.
545		https://doi.org/10.1128/mBio.00221-18.
546	[33]	Wang M, Cao R, Zhang L, Yang X, Liu J, Xu M, et al. Remdesivir and chloroquine
547		effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell
548		Res 2020;30:269–71. https://doi.org/10.1038/s41422-020-0282-0.

549	[34]	Delang L, Abdelnabi R, Neyts J. Favipiravir as a potential countermeasure against
550		neglected and emerging RNA viruses. Antiviral Res 2018;153:85–94.
551		https://doi.org/10.1016/j.antiviral.2018.03.003.
552	[35]	Koren G, King S, Knowles S, Phillips E. Ribavirin in the treatment of SARS: A new
553		trick for an old drug? CMAJ 2003;168:1289-92.
554	[36]	Chan KW, Wong VT, Tang SCW. COVID-19: An Update on the Epidemiological,
555		Clinical, Preventive and Therapeutic Evidence and Guidelines of Integrative Chinese-
556		Western Medicine for the Management of 2019 Novel Coronavirus Disease. Am J
557		Chin Med 2020:1–26. https://doi.org/10.1142/s0192415x20500378.
558	[37]	Wang R-R, Yang Q-H, Luo R-H, Peng Y-M, Dai S-X, Zhang X-J, et al. Azvudine, a
559		novel nucleoside reverse transcriptase inhibitor showed good drug combination
560		features and better inhibition on drug-resistant strains than lamivudine in vitro. PLoS
561		One 2014;9:e105617. https://doi.org/10.1371/journal.pone.0105617.
562	[38]	Rolain J-M, Colson P, Raoult D. Recycling of chloroquine and its hydroxyl analogue
563		to face bacterial, fungal and viral infections in the 21st century. Int J Antimicrob
564		Agents 2007;30:297–308. https://doi.org/10.1016/j.ijantimicag.2007.05.015.
565	[39]	Touret F, de Lamballerie X. Of chloroquine and COVID-19. Antiviral Res 2020;177.
566		https://doi.org/10.1016/j.antiviral.2020.104762.
567	[40]	Colson P, Rolain J-M, Raoult D. Chloroquine for the 2019 novel coronavirus SARS-
568		CoV-2. Int J Antimicrob Agents 2020;55:105923.
569		https://doi.org/10.1016/j.ijantimicag.2020.105923.
570	[41]	Savarino A, Boelaert JR, Cassone A, Majori G, Cauda R. Antiviral effects of
571		chloroquine Effects of chloroquine on viral infections \square : an old drug against today 's
572		$diseases \ \square\ ?\ Lancet\ 2003; 3:722-7.\ https://doi.org/10.1016/S1473-3099(03)00806-5.$

573	[42]	Savarino A, Di Trani L, Donatelli I, Cauda R, Cassone A. New insights into the
574		antiviral effects of chloroquine. Lancet Infect Dis 2006;6:67–9.
575		https://doi.org/10.1016/S1473-3099(06)70361-9.
576	[43]	Gautret P, Lagier J-C, Parola P, Hoang VT, Meddeb L, Mailhe M, et al.
577		Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an
578		open-label non-randomized clinical trial. Int J Antimicrob Agents 2020:105949.
579		https://doi.org/10.1016/j.ijantimicag.2020.105949.
580	[44]	Gao J, Tian Z, Yang X. Breakthrough: Chloroquine phosphate has shown apparent
581		efficacy in treatment of COVID-19 associated pneumonia in clinical studies. Biosci
582		Trends 2020;14:72–3. https://doi.org/10.5582/bst.2020.01047.
583	[45]	Mehta P, McAuley DF, Brown M, Sanchez E, Tattersall RS, Manson JJ, et al.
584		COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet
585		(London, England) 2020;395:1033-4. https://doi.org/10.1016/S0140-6736(20)30628-
586		0.
587	[46]	Chen C, Zhang XR, Ju ZY, He WF. [Advances in the research of cytokine storm
588		mechanism induced by Corona Virus Disease 2019 and the corresponding
589		immunotherapies]. Zhonghua Shao Shang Za Zhi 2020;36:E005.
590		https://doi.org/10.3760/cma.j.cn501120-20200224-00088.
591	[47]	Chen L, Liu HG, Liu W, Liu J, Liu K, Shang J, et al. [Analysis of clinical features of
592		29 patients with 2019 novel coronavirus pneumonia]. Zhonghua Jie He Hu Xi Za
593		Zhi 2020;43:203–8. https://doi.org/10.3760/cma.j.issn.1001-0939.2020.03.013.
594	[48]	Xu X, Han M, Li T, Sun W, Wang D, Fu B, et al. Effective Treatment of Severe
595		COVID-19 Patients with Tocilizumab. n.d.
596	[49]	Demidowich AP, Davis AI, Dedhia N, Yanovski JA. Colchicine to decrease NLRP3-

597		activated inflammation and improve obesity-related metabolic dysregulation. Med
598		Hypotheses 2016;92:67–73. https://doi.org/10.1016/j.mehy.2016.04.039.
599	[50]	Min J-Y, Jang YJ. Macrolide therapy in respiratory viral infections. Mediators
600		Inflamm 2012;2012:649570. https://doi.org/10.1155/2012/649570.
601	[51]	Kanoh S, Rubin BK. Mechanisms of action and clinical application of macrolides as
602		immunomodulatory medications. Clin Microbiol Rev 2010;23:590-615.
603		https://doi.org/10.1128/CMR.00078-09.
604	[52]	Russell CD, Millar JE, Baillie JK. Clinical evidence does not support corticosteroid
605		treatment for 2019-nCoV lung injury. Lancet 2020;395:473-5.
606		https://doi.org/10.1016/S0140-6736(20)30317-2.
607	[53]	Important Announcement of new SSC Guidelines – COVID-19 - ESICM n.d.
608		https://www.esicm.org/ssc-covid19-guidelines/ (accessed April 2, 2020).
609	[54]	Sallard E, Lescure F-X, Yazdanpanah Y, Mentre F, Peiffer-Smadja N, C-20-15
610		DisCoVeRy French Steering Committee. Type 1 interferons as a potential treatment
611		against COVID-19. Antiviral Res 2020:104791.
612		https://doi.org/10.1016/j.antiviral.2020.104791.
613	[55]	Angiotensin converting enzyme (ACE) inhibitors and angiotensin receptor blockers in
614		COVID-19 - CEBM n.d. https://www.cebm.net/covid-19/angiotensin-converting-
615		enzyme-ace-inhibitors-and-angiotensin-receptor-blockers-in-covid-19/ (accessed April
616		2, 2020).
617	[56]	Chen Y, Guo Y, Pan Y, Zhao ZJ. Structure analysis of the receptor binding of 2019-
618		nCoV. Biochem Biophys Res Commun 2020.
619		https://doi.org/10.1016/j.bbrc.2020.02.071.
620	[57]	Heurich A, Hofmann-Winkler H, Gierer S, Liepold T, Jahn O, Pohlmann S.

621		TMPRSS2 and ADAM17 Cleave ACE2 Differentially and Only Proteolysis by
622		TMPRSS2 Augments Entry Driven by the Severe Acute Respiratory Syndrome
623		Coronavirus Spike Protein. J Virol 2014;88:1293–307.
624		https://doi.org/10.1128/jvi.02202-13.
625	[58]	Danser AHJ, Epstein M, Batlle D. Renin-Angiotensin System Blockers and the
626		COVID-19 Pandemic: At Present There Is No Evidence to Abandon Renin-
627		Angiotensin System Blockers. Hypertens (Dallas, Tex 1979)
628		2020:HYPERTENSIONAHA12015082.
629		https://doi.org/10.1161/HYPERTENSIONAHA.120.15082.
630	[59]	Hanff TC, Harhay MO, Brown TS, Cohen JB, Mohareb AM. Is There an Association
631		Between COVID-19 Mortality and the Renin-Angiotensin System-a Call for
632		Epidemiologic Investigations. Clin Infect Dis 2020.
633		https://doi.org/10.1093/cid/ciaa329.
634	[60]	Yamawaki H, Futagami S, Kaneko K, Agawa S, Higuchi K, Murakami M, et al.
634 635	[60]	Yamawaki H, Futagami S, Kaneko K, Agawa S, Higuchi K, Murakami M, et al. Camostat Mesilate, Pancrelipase, and Rabeprazole Combination Therapy Improves
	[60]	
635	[60]	Camostat Mesilate, Pancrelipase, and Rabeprazole Combination Therapy Improves
635 636	[60]	Camostat Mesilate, Pancrelipase, and Rabeprazole Combination Therapy Improves Epigastric Pain in Early Chronic Pancreatitis and Functional Dyspepsia with
635 636 637	[60]	Camostat Mesilate, Pancrelipase, and Rabeprazole Combination Therapy Improves Epigastric Pain in Early Chronic Pancreatitis and Functional Dyspepsia with Pancreatic Enzyme Abnormalities. Digestion 2019;99:283–92.
635636637638		Camostat Mesilate, Pancrelipase, and Rabeprazole Combination Therapy Improves Epigastric Pain in Early Chronic Pancreatitis and Functional Dyspepsia with Pancreatic Enzyme Abnormalities. Digestion 2019;99:283–92. https://doi.org/10.1159/000492813.
635636637638639		Camostat Mesilate, Pancrelipase, and Rabeprazole Combination Therapy Improves Epigastric Pain in Early Chronic Pancreatitis and Functional Dyspepsia with Pancreatic Enzyme Abnormalities. Digestion 2019;99:283–92. https://doi.org/10.1159/000492813. Hoffmann M, Kleine-Weber H, Krüger N, Müller M, Drosten C, Pöhlmann S. The
635 636 637 638 639 640		Camostat Mesilate, Pancrelipase, and Rabeprazole Combination Therapy Improves Epigastric Pain in Early Chronic Pancreatitis and Functional Dyspepsia with Pancreatic Enzyme Abnormalities. Digestion 2019;99:283–92. https://doi.org/10.1159/000492813. Hoffmann M, Kleine-Weber H, Krüger N, Müller M, Drosten C, Pöhlmann S. The novel coronavirus 2019 (2019-nCoV) uses the SARS-coronavirus receptor ACE2 and
635 636 637 638 639 640 641		Camostat Mesilate, Pancrelipase, and Rabeprazole Combination Therapy Improves Epigastric Pain in Early Chronic Pancreatitis and Functional Dyspepsia with Pancreatic Enzyme Abnormalities. Digestion 2019;99:283–92. https://doi.org/10.1159/000492813. Hoffmann M, Kleine-Weber H, Krüger N, Müller M, Drosten C, Pöhlmann S. The novel coronavirus 2019 (2019-nCoV) uses the SARS-coronavirus receptor ACE2 and the cellular protease TMPRSS2 for entry into target cells. BioRxiv
635 636 637 638 639 640 641 642	[61]	Camostat Mesilate, Pancrelipase, and Rabeprazole Combination Therapy Improves Epigastric Pain in Early Chronic Pancreatitis and Functional Dyspepsia with Pancreatic Enzyme Abnormalities. Digestion 2019;99:283–92. https://doi.org/10.1159/000492813. Hoffmann M, Kleine-Weber H, Krüger N, Müller M, Drosten C, Pöhlmann S. The novel coronavirus 2019 (2019-nCoV) uses the SARS-coronavirus receptor ACE2 and the cellular protease TMPRSS2 for entry into target cells. BioRxiv 2020:2020.01.31.929042. https://doi.org/10.1101/2020.01.31.929042.

646 Antiviral Drug Arbidol Inhibits Zika Virus. Sci Rep 2018;8:8989. 647 https://doi.org/10.1038/s41598-018-27224-4. 648 [64] Hulseberg CE, Fénéant L, Szymańska-de Wijs KM, Kessler NP, Nelson EA, 649 Shoemaker CJ, et al. Arbidol and Other Low-Molecular-Weight Drugs That Inhibit 650 Lassa and Ebola Viruses. J Virol 2019;93. https://doi.org/10.1128/jvi.02185-18. 651 [65] Shi L, Xiong H, He J, Deng H, Li Q, Zhong Q, et al. Antiviral activity of arbidol 652 against influenza A virus, respiratory syncytial virus, rhinovirus, coxsackie virus and 653 adenovirus in vitro and in vivo. Arch Virol 2007;152:1447–55. 654 https://doi.org/10.1007/s00705-007-0974-5. 655 [66] Deng P, Zhong D, Yu K, Zhang Y, Wang T, Chen X. Pharmacokinetics, metabolism, 656 and excretion of the antiviral drug arbidol in humans. Antimicrob Agents Chemother 657 2013;57:1743–55. https://doi.org/10.1128/AAC.02282-12. 658 [67] Glushkov RG, Gus'kova TA, Krylova LI, Nikolaeva IS. [Mechanisms of arbidole's 659 immunomodulating action]. Vestn Ross Akad Meditsinskikh Nauk 1999:36–40. 660 Deng L, Li C, Zeng Q, Liu X, Li X, Zhang H, et al. Arbidol combined with LPV/r [68] 661 versus LPV/r alone against Corona Virus Disease 2019:a retrospective cohort study. J 662 Infect 2020. https://doi.org/10.1016/j.jinf.2020.03.002. 663 [69] Sahr F, Ansumana R, Massaquoi TA, Idriss BR, Sesay FR, Lamin JM, et al. 664 Evaluation of convalescent whole blood for treating Ebola Virus Disease in Freetown, 665 Sierra Leone. J Infect 2017;74:302–9. https://doi.org/10.1016/j.jinf.2016.11.009. 666 [70] Wong VWS, Dai D, Wu AKL, Sung JJY. Treatment of severe acute respiratory 667 syndrome with convalescent plasma. Hong Kong Med J 2003;9:199–201. 668 [71] Cheng Y, Wong R, Soo YOY, Wong WS, Lee CK, Ng MHL, et al. Use of 669 convalescent plasma therapy in SARS patients in Hong Kong. Eur J Clin Microbiol

670		Infect Dis 2005;24:44–6. https://doi.org/10.1007/s10096-004-1271-9.
671	[72]	Soo YOY, Cheng Y, Wong R, Hui DS, Lee CK, Tsang KKS, et al. Retrospective
672		comparison of convalescent plasma with continuing high-dose methylprednisolone
673		treatment in SARS patients. Clin Microbiol Infect 2004;10:676–8.
674		https://doi.org/10.1111/j.1469-0691.2004.00956.x.
675	[73]	Mair-Jenkins J, Saavedra-Campos M, Baillie JK, Cleary P, Khaw F-M, Lim WS, et al.
676		The effectiveness of convalescent plasma and hyperimmune immunoglobulin for the
677		treatment of severe acute respiratory infections of viral etiology: a systematic review
678		and exploratory meta-analysis. J Infect Dis 2015;211:80–90.
679		https://doi.org/10.1093/infdis/jiu396.
680	[74]	Arabi YM, Hajeer AH, Luke T, Raviprakash K, Balkhy H, Johani S, et al. Feasibility
681		of Using Convalescent Plasma Immunotherapy for MERS-CoV Infection, Saudi
682		Arabia. Emerg Infect Dis 2016;22:1554–61. https://doi.org/10.3201/eid2209.151164.
683	[75]	Cao W-C, Liu W, Zhang P-H, Zhang F, Richardus JH. Disappearance of antibodies to
684		SARS-associated coronavirus after recovery. N Engl J Med 2007;357:1162–3.
685		https://doi.org/10.1056/NEJMc070348.
686	[76]	Loy H, Kuok DIT, Hui KPY, Choi MHL, Yuen W, Nicholls JM, et al. Therapeutic
687		Implications of Human Umbilical Cord Mesenchymal Stromal Cells in Attenuating
688		Influenza A(H5N1) Virus-Associated Acute Lung Injury. J Infect Dis 2019;219:186–
689		96. https://doi.org/10.1093/infdis/jiy478.
690	[77]	Leng Z, Zhu R, Hou W, Feng Y, Yang Y, Han Q, et al. Transplantation of ACE2-
691		Mesenchymal Stem Cells Improves the Outcome of Patients with COVID-19
692		Pneumonia. Aging Dis 2020;11:216. https://doi.org/10.14336/ad.2020.0228.
693	[78]	Yu B, Zhang X, Li X. Exosomes derived from mesenchymal stem cells. Int J Mol Sci

694		2014;15:4142–57. https://doi.org/10.3390/ijms15034142.
695	[79]	Yin K, Wang S, Zhao RC. Exosomes from mesenchymal stem/stromal cells: A new
696		therapeutic paradigm. Biomark Res 2019;7. https://doi.org/10.1186/s40364-019-0159-
697		X.
698	[80]	Di Paolo N, Bocci V, Gaggiotti E. Ozone therapy. Int J Artif Organs 2004;27:168–75.
699		https://doi.org/10.1177/039139880402700303.
700	[81]	Infection prevention and control n.d. https://www.who.int/emergencies/diseases/novel-
701		coronavirus-2019/technical-guidance/infection-prevention-and-control (accessed April
702		2, 2020).
703	[82]	COVID-19 n.d. https://www.ecdc.europa.eu/en/covid-19-pandemic (accessed April 2,
704		2020).
705	[83]	Moderna's COVID-19 vaccine could reach healthcare workers this fall FierceBiotech
706		n.d. https://www.fiercebiotech.com/biotech/moderna-s-covid-19-vaccine-could-reach-
707		healthcare-workers-fall (accessed April 2, 2020).
708	[84]	Johnson & Johnson identifies lead COVID-19 vaccine candidate n.d.
709		https://www.drugtargetreview.com/news/58911/johnson-johnson-identifies-lead-
710		covid-19-vaccine-candidate/ (accessed April 2, 2020).
711	[85]	WHO R&D Blueprint novel Coronavirus COVID-19 Therapeutic Trial Synopsis.
712		2020.
713	[86]	Murray JF, Matthay MA, Luce JM, Flick MR. An expanded definition of the adult
714		respiratory distress syndrome. Am Rev Respir Dis 1988;138:720-3.
715		https://doi.org/10.1164/ajrccm/138.3.720.
716	[87]	Fine MJ, Auble TE, Yealy DM, Hanusa BH, Weissfeld LA, Singer DE, et al. A
717		prediction rule to identify low-risk patients with community-acquired pneumonia. N

718 Engl J Med 1997;336:243–50. https://doi.org/10.1056/NEJM199701233360402. 719 [88] Shi Y, Wang Y, Shao C, Huang J, Gan J, Huang X, et al. COVID-19 infection: the 720 perspectives on immune responses. Cell Death Differ 2020:1–4. 721 https://doi.org/10.1038/s41418-020-0530-3. 722 Wu J, Li W, Shi X, Chen Z, Jiang B, Liu J, et al. Early antiviral treatment contributes [89] 723 to alleviate the severity and improve the prognosis of patients with novel coronavirus 724 disease (COVID-19). J Intern Med 2020. https://doi.org/10.1111/joim.13063. 725 [90] To KK-W, Tsang OT-Y, Leung W-S, Tam AR, Wu T-C, Lung DC, et al. Temporal 726 profiles of viral load in posterior or pharyngeal saliva samples and serum antibody 727 responses during infection by SARS-CoV-2: an observational cohort study. Lancet 728 Infect Dis 2020;3099:1–10. https://doi.org/10.1016/S1473-3099(20)30196-1. 729 [91] Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients 730 infected with 2019 novel coronavirus in Wuhan, China. Lancet 2020;395:497-506. 731 https://doi.org/10.1016/S0140-6736(20)30183-5. 732 [92] Stebbing J, Phelan A, Griffin I, Tucker C, Oechsle O, Smith D, et al. COVID-19: combining antiviral and anti-inflammatory treatments. Lancet Infect Dis 2020;20:400-733 734 2. https://doi.org/10.1016/S1473-3099(20)30132-8. 735 [93] Diagnosis and Treatment Protocol for COVID-19 (Trial Version 7) n.d. 736 http://en.nhc.gov.cn/2020-03/29/c_78469.htm (accessed April 2, 2020). 737 [94] Holshue ML, DeBolt C, Lindquist S, Lofy KH, Wiesman J, Bruce H, et al. First case 738 of 2019 novel coronavirus in the United States. N Engl J Med 2020;382:929-36. 739 https://doi.org/10.1056/NEJMoa2001191. 740 [95] NIH clinical trial of investigational vaccine for COVID-19 begins | National Institutes 741 of Health (NIH) n.d. https://www.nih.gov/news-events/news-releases/nih-clinical-trial742 investigational-vaccine-covid-19-begins (accessed April 2, 2020). 743 [96] Chloroquine/ Hydroxychloroquine Prevention of Coronavirus Disease (COVID-19) in 744 the Healthcare Setting - Full Text View - ClinicalTrials.gov n.d. 745 https://clinicaltrials.gov/ct2/show/NCT04303507 (accessed April 2, 2020). 746 [97] Li X, Geng M, Peng Y, Meng L, Lu S. Molecular immune pathogenesis and diagnosis 747 of COVID-19. J Pharm Anal 2020. https://doi.org/10.1016/j.jpha.2020.03.001. 748 [98] Cepheid | Xpert® Xpress SARS-CoV-2 has received FDA Emergency Use 749 Authorization n.d. https://www.cepheid.com/coronavirus (accessed April 2, 2020). 750 [99] Detect COVID-19 in as Little as 5 Minutes | Abbott Newsroom n.d. 751 https://www.abbott.com/corpnewsroom/product-and-innovation/detect-covid-19-in-as-752 little-as-5-minutes.html (accessed April 4, 2020). 753 [100] Report of the WHO-China Joint Mission on Coronavirus Disease 2019 (COVID-19) 754 n.d. https://www.who.int/publications-detail/report-of-the-who-china-joint-mission-755 on-coronavirus-disease-2019-(covid-19) (accessed April 2, 2020). 756 757

759 Figures:

760 Figure 1. Systematic review Flow Chart.




Figure 2. Currently tested therapeutic molecules targeting different steps of SARS-CoV-2 life cycle.





Figure 3.General and supportive therapeutic interventions tested for novel coronavirus disease (COVID-19).



781 Figure 4. Number of trials reported by the median of the total number of planned inclusions per trial for the most common treatments.

783

784





Figure 5. Number of trials per total number of planned inclusions for the ten most frequently assessed treatments.



Note: The size of the circle corresponds to the addition of the total numbers of planned inclusions for all trials evaluating one of the treatments

790 Tables:

791 Table 1. Treatment interventions currently being evaluated for the novel coronavirus disease

792 (COVID-19) globally.

Therapeutic	Countries	No. of trials	No. of RCTs	Other agents used in combination
Intervention		being tested	(% of trials per	
			intervention)	
TCMs	China	92	61 (66.3)	IFNα, LPV/r, Ribavirin, Chloroquine,
				Umifenovir, Ulinastatin
Antimalaria drugs	China, France,	34	27 (79.4)	Azithromycin, LPV/r, DRV/r or c,
(hydroxychloroquine,	Germany, Mexico,			Favipiravir, Oseltamivir, Umifenovir,
chloroquine,	Norway, Spain, Brazil,			IFNα
dihydroartemisinin	Canada			
piperaquine)				
Lopinavir ± ritonavir	China, Thailand, Hong	32	31 (96.8)	Chloroquine, IFN α , IFN β , Navaferon,
$(LPV \pm r)$	Kong, United			Thymosin a1, FTC/TAF, Ribavirin,
	Kingdom, Europe,			Ebastine, Oseltamivir, Favipiravir,
	South Korea, Canada			TCM
Cell therapy	China, USA, Brazil,	30	18 (60)	Ruxolitinib
	Jordan			
Interferon (IFNα,	China, UK, Hong	22	22 (100)	Umifenovir, Dihydroartemisinine
IFN $\alpha 2\beta$, IFN β ,	Kong, Europe			piperaquine, TCM, Bromhexine,
(III)				Favipiravir, LPV/r, Ribavirin,
rSIFN-co)				Ebastine, Danoprevir/r, Thalidomide,
				Methylprednisolone, TTF2
Anti-IL-6 mAb	China, Italy, France,	14	9 (64.3)	Favipiravir, Adalimumab
(Tocilizumab,	Switzerland, Denmark,			
Sarilumab)	USA, Canada, Global			

Dietary/Supportive	China, Egypt	13	10 (76.9)	N/A
Corticosteroids	China, UK, Italy	11	9 (81.8)	IFN α Umifenovir, Thalidomide
Umifenovir	China	11	11 (100)	Novaferon, IFNα, IFNα2β, Dihydroartemisinine piperaquine, Bromhexine, Favipiravir, Thalidomide, Methylprednisolone
Convalescent plasma	China, Italy	10	7 (70)	N/A
Adjuvant Device	China	9	3 (33.3)	N/A
Favipiravir	China, Thailand	8	8 (100)	Tocilizumab, Bromhexine, IFNα, Umifenovir, (Hydroxy)chloroquine, LPV/r, DRV/r
Remdesivir	Global, Europe, USA, China	8	7 (87.5)	Hydroxychloroquine
Ventilation/ Oxygenation strategies	China	7	0 (0)	N/A
Macrolides (azithromycin, carrimycin)	China, Brazil, Denmark	4	4 (100)	Hydroxychloroquine
Inhaled Gases	China, USA, Italy	4	4 (100)	N/A
JAK inhibitors (Jakotinib, Ruxolitinib, Baricitinib)	China, Italy, Canada	4	2 (50)	Cell therapy, Ritonavir
ACE inhibitor / ARBs	China, USA	3	2 (66.7)	N/A
Azvudine	China	3	1 (33.3)	N/A
Danoprevir/ritonavir	China	3	3 (100)	IFN

Darunavir/cobicistat	China, Thailand	3	3 (100)	Thymosin a1, Oseltamivir,
(DRV/r)				Hydroxychloroquine, Favipiravir
Pirferidone	China	3	3 (100)	N/A
Anti-PD-1 mAb	China	3	3 (100)	N/A
Oseltamivir	Thailand, China	3	3 (100)	Hydroxychloroquine, DRV/r, LPV/r
Thymosin a1	China	3	3 (100)	DRV/c, LPV/r
Adalimumab	China	2	2 (100)	Tocilizumab
Bevazicumab	China, Italy	2	1 (50)	N/A
Colchicine	Italy, Canada	2	2 (100)	N/A
Novaferon	China	2	2 (100)	LPV/r, Umifenovir
Ribavirin	China, Hong Kong	2	2 (100)	IFN, LPV/r
Thalidomide	China	2	2 (100)	IFNα, Umifenovir,
				Methylprednisolone
Ulinastatin	China	2	1 (50)	TCM
ASC09/ritonavir	China	2	2 (100)	N/A
Intravenous	China	2	2 (100)	N/A
Immunoglobulin				
Acetylcysteine	China	1	1 (100)	N/A
Antiviral peptide LL-37	China	1	0 (0)	N/A
Baloxavir Marboxil	China	1	1 (100)	N/A
Bismuth potassium	China	1	1 (100)	N/A
Bronchoscopic alveolar	China	1	0 (0)	N/A
lavage				

CD24Fc	USA	1	1 (100)	N/A
Dipyridamole	China	1	1 (100)	N/A
Ebastine	China	1	1 (100)	IFNα, LPV/r
Eculizumab	N/A	1	0 (0)	N/A
Enoxaparin	China	1	1 (100)	N/A
Escin	Italy	1	0 (0)	N/A
Fingolimod	China	1	0 (0)	N/A
FTC/TAF	China	1	1 (100)	LPV/r
hrIL-2	China	1	1 (100)	N/A
Inactivated	China	1	1 (100)	N/A
mycobacterial vaccine				
Itraconazole	Belgium	1	1 (100)	N/A
Ixekizuman	China	1	1 (100)	IFNα, Ribavirin, Chloroquine, LPV/r,
				Umifenovir
Leflunomide	China	1	1 (100)	N/A
M1	China	1	1 (100)	N/A
Polyinosinic/	China	1	1 (100)	N/A
polycytidylic acid				
rhG-CSF	China	1	1 (100)	N/A
Sargramostin (GM-CSF)	Belgium	1	1 (100)	N/A
Sildenafil	China	1	0 (0)	N/A
Siltuximab	Italy	1	0 (0)	N/A
Suramin	China	1	0 (0)	N/A

T89	N/A	1	1 (100)	N/A
TFF-2	China	1	1 (100)	IFN-κ
TMPRSS2 inhibitor (camostat mesylate)	Denmark	1	1 (100)	N/A
Tranilast	China	1	1 (100)	N/A
VIP	USA, Israel	1	1 (100)	N/A
vMIP	China	1	0 (0)	N/A
Meplazumab (anti-CD147)	China	1	1 (100)	N/A
Sodium Aescinate	China	1	1 (100)	N/A
Triazavirin	China	1	1 (100)	N/A

ACE: Angiotensin converting enzyme, Anti-PD-1 mAb: Anti Program Cell Death Protein-1 monoclonal antibody, ARBs: Angiotensin II receptor blockers, CD24Fc: CD24 extracellular domain-IgG1 Fc domain recombinant fusion protein, DRV/r or c: Darunavir/ritonavir or cobicistat, FTC/TAF: Emtricitabine/Tenofovir alafenamide, GM-CSF: Granulocyte Macrophage-Colony Stimulating Factor, hrIL-2: human recombinant interleukin 2, IFNα: Interferon alpha, IFNβ: Interferon beta, INFκ: Interferon kappa, IL: Interleukin, JAK: Janus Kinases, LPV/r: Lopinavir/ritonavir, M1: Type I Macrophage, N/A: Not applicable, RCTs: Randomised controlled trials, rhG-CSF: recombinant human Granulocyte-Colony Stimulating Factor, TCMs: Traditional Chinese Medicines, TMPRSS2: Transmembrane Protease Serine 2, TTF-2: Transcription Termination Factor 2, UK: United Kingdom, USA: United States of America, VIP: Vasoactive Intestinal Peptide, vMIP: viral Macrophage Inflammatory Protein.

Table 2. Prevention interventions currently being evaluated for the novel coronavirus disease(COVID-19) globally.

Prevention	Countries	No. of trials	No. of RCTs	Other agents used in combination
intervention		being tested	(% of trials per	
			intervention)	
TCMs	China	10	3 (30)	N/A
Antimalaria Drugs	China, USA, Mexico,	6	6 (100)	Umifenovir, DRV/c
	UK, Spain			
Vaccine	USA, China	4	0 (0)	N/A
Health education	China, Hungary	3	2 (66.7)	TCM
IFNα1β	China	2	0 (0)	Thymosin a1
Darunavir/cobicistat	Spain	1	1 (100)	Chloroquine
Lopinavir/ritonavir	Canada	1	1 (100)	N/A
Mask	Canada	1	1 (100)	N/A
PUL-042	USA	1	1 (100)	N/A
Thymosin a1	China	1	0 (0)	$IFN\alpha 1\beta$
Umifenovir	China	1	1 (100)	Hydroxychloroquine

DRV/c: Darunavir/cobicistat, IFNα: Interferon alpha, LPV/r: Lopinavir/ritonavir, N/A: Not applicable, RCTs: Randomised controlled trials, TCMs: Traditional Chinese Medicines, UK: United Kingdom, USA: United States of America.

Table 3. Description of the clinical trials registered for the treatment and prevention of COVID-19.

Study characteristics		Treatment studies	Prevention studies
		N = 198 (%)	N = 16 (%)
Study phase			
	Phase I	9 (5)	3 (19)
	Phase II*	31 (16)	2 (13)
	Phase III**	35 (18)	6 (38)
	Phase IV	40 (20)	1 (6)
	Unspecified	83 (42)	4 (25)
Study design			
	Randomised	150 (76)	10 (63)
	Non-randomised	21 (11)	3 (19)
	Single-arm	27 (14)	3 (19)
Blinding			
	Double-blind	31 (16)	6 (38)
	Single-blind	16 (8)	2 (13)
	Open-label	73 (37)	5 (31)
	Non-applicable†	29 (15)	3 (19)
	Unspecified	49 (25)	0 (0)
Total number of planned inc	lusions		
	<50	62 (31)	1 (6)

	50-100	41 (21)	0 (0)
	100-150	32 (16)	3 (19)
	150-200	9 (5)	0 (0)
	200-250	15 (8)	1 (6)
	≥250	39 (20)	11 (69)
Primary endpoint			
	Clinical	128 (65)	13 (81)
	Virological	39 (20)	2 (13)
	Radiological	19 (10)	0 (0)
	Immunological/biological	12 (6)	1 (6)

^{*}Including phase I/II trials; **Including phase II/III trials; †: Single-arm or factorial trials.